Urology Resident & Doctoral Student in Clinical Epidemiology at the University of Toronto | Alum of McGill Medicine & Harvard Chan School of Public Health | he/him
David-Dan Nguyen
Manufacturers of >90% of FDA-listed #AI- and machine learning–enabled devices publicly disclosed no payments to clinicians or teaching hospitals from 2017-2023, but the $ amount of general payments doubled in that time frame.
ja.ma/3VVS9WB
Updated review finds PSA screening linked to lower prostate cancer mortality over the long term. bit.ly/3QMI6nO
In @jama.com, we identify a blind spot for FDA-listed AI/ML devices 🤖🔍
Over 90% have no reported manufacturer payments to clinicians or hospitals in Open Payments (US disclosure database)
As AI enters care, transparency can’t lag
jamanetwork.com/journals/jam...
In conversation with @rhodeshouse.ox.ac.uk about how we define disease and how that shapes everything from mechanism to care. This piece reflects some of the questions that led me to my current 🔬 work.
Ft. @ndorms.bsky.social @ajclarke.bsky.social @ox.ac.uk @utoronto.ca @healthsciences.mcgill.ca
Is it time for Canada to revisit its approach to prostate cancer screening?
www.sciencedirect.com/science/arti...
